# US 2005/0232897 A1 · Mucosal cytotoxic T lymphocyte responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232897 A1
- Document ID: US20050232897A1
- Status: Published application
- Kind: A1
- Application number: 10/815,340
- Filed: 2004-03-30
- Published: 2005-10-20
- Earliest claimed: 1997-09-11
- Assignees: Health and Human Services, The Government of the United States of America, as Represented by
- Inventors: Jay Berzofsky; Igor Belyakov; Michael Derby; Brian Kelsall; Warren Strober
- Web page: https://patentgrep.com/patent/US20050232897A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/541: {Mucosal route}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55538: {IL-12}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y10S 530/826: Viruses
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface.

## Claims

### Claim 1

A method for inducing a protective mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a mucosal tissue of the subject with a composition comprising a purified soluble antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein the soluble antigen is an antigenic peptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein said composition further comprises an adjuvant.

### Claim 4 (depends on 3)

The method of claim 3, wherein the adjuvant is selected from cholera toxin (CT), mutant cholera toxin (MCT), or mutant-E. coli heat labile enterotoxin (MLT).

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering a purified cytokine to the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cytokine is contacted with a mucosal surface of the subject.

### Claim 7 (depends on 5)

The method of claim 5, wherein the purified cytokine is selected from granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor a (TNFa).

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering purified interferon-γ to the subject.

### Claim 9 (depends on 8)

The method of claim 8, wherein the purified interferon-γ is contacted with a mucosal surface of the subject.

### Claim 10 (depends on 5)

The method of claim 5, further comprising administering purified interferon-γ to the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the purified interferon-γ is contacted with a mucosal surface of the subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein said composition further comprises a purified cytokine selected from granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor.

### Claim 13 (depends on 1)

The method of claim 1, wherein said composition further comprises purified interferon-γ.

### Claim 14 (depends on 12)

The method of claim 12, wherein said composition further comprises purified interferon-γ.

### Claim 15 (depends on 1)

The method of claim 1, wherein the antigen is a peptide derived from a pathogenic virus.

### Claim 16 (depends on 15)

The method of claim 15, wherein the pathogenic virus is HIV-1.

### Claim 17 (depends on 15)

The method of claim 15, wherein the pathogenic virus is influenza virus.

### Claim 18 (depends on 15)

The method of claim 15, wherein the pathogenic virus is rotavirus.

### Claim 19 (depends on 1)

The method of claim 1, wherein the antigen is a peptide derived from a pathogenic bacterium or protozoan.

### Claim 20 (depends on 1)

The method of claim 1, wherein the antigen is a tumor-associated peptide.

### Claim 21 (depends on 1)

The method of claim 1, wherein the antigen is a peptide comprising an HIV-1 cluster peptide vaccine construct (CLUVAC) selected from the group consisting of:
(SEQ ID NO:1)
EQMHEDIISLWDQSLKPCVKRIQRGPGRAFVTIGK,
(SEQ ID NO:2)
KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFVTIGK,
(SEQ ID NO:3)
RDNWRSELYKYKVVKIEPLGVAPTRIQRGPGRAFVTIGK,
(SEQ ID NO:4)
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK,
(SEQ ID NO:5)
DRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK,
(SEQ ID NO:6)
DRVIEVVQGAYRAIRRIQRGPGRAFVTIGK,
(SEQ ID NO:7)
AQGAYRAIRHIPRRIRRIQRGPGRAFVTIGK,
(SEQ ID NO:8)
EQMHEDIISLWDQSLKPCVKRIHIGPGRAFYTTKN,
(SEQ ID NO:9)
KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN,
(SEQ ID NO:10)
RDNWRSELYKYKVVKIEPLGVAPTRIHIGPGRAFYTTKN,
SEQ ID NO:11)
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN,
(SEQ ID NO:12)
DRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN,
(SEQ ID NO:13)
DRVIEVVQGAYRAIRRIHIGPGRAFYTTKN
and
(SEQ ID NO:14)
AQGAYRAIRHIPRRIRRIHIGPGRAFYTTKN.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The method of claim 21, wherein the HIV-1 CLUVAC is HIV-1 CLUVAC PCLUS3-18MN (SEQ ID NO:9).

### Claim 24 (depends on 21)

The method of claim 21, wherein the HIV-1 CLUVAC is HIV-1 CLUVAC PCLUS 6.1-18MN (SEQ ID NO:12).

### Claim 25

A method for inducing a protective mucosal CTL response in a subject, comprising contacting a mucosal tissue of the subject with a composition comprising a soluble antigen, wherein said composition does not comprise an adjuvant.

### Claim 26 (depends on 25)

The method of claim 25, further comprising administering a purified cytokine to the subject.

### Claim 27 (depends on 25)

The method of claim 25, wherein the cytokine is contacted with a mucosal surface of the subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein the purified cytokine is selected from granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor a (TNFa).

### Claim 29 (depends on 25)

The method of claim 25, further comprising administering purified interferon-γ to the subject.

### Claim 30 (depends on 29)

The method of claim 29, wherein the purified interferon-γ is contacted with a mucosal surface of the subject.

### Claim 31 (depends on 26)

The method of claim 26, further comprising administering purified interferon-γ to the subject.

### Claim 32 (depends on 31)

The method of claim 31, wherein the purified interferon-γ is contacted with a mucosal surface of the subject.

### Claim 33 (depends on 25)

The method of claim 25, wherein said composition further comprises a purified cytokine selected from granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin-12 (IL-12) or tumor necrosis factor.

### Claim 34 (depends on 25)

The method of claim 25, wherein said composition further comprises purified interferon-γ.

### Claim 35 (depends on 33)

The method of claim 33, wherein said composition further comprises purified interferon-γ.

### Claim 36 (depends on 25)

The method of claim 25, wherein the antigen is a peptide derived from a pathogenic virus.

### Claim 37 (depends on 36)

The method of claim 36, wherein the pathogenic virus is HIV-1.

### Claim 38 (depends on 36)

The method of claim 36, wherein the pathogenic virus is influenza virus.

### Claim 39 (depends on 36)

The method of claim 36, wherein the pathogenic virus is rotavirus.

### Claim 40 (depends on 25)

The method of claim 25, wherein the antigen is a peptide derived from a pathogenic bacterium or protozoan.

### Claim 41 (depends on 25)

The method of claim 25, wherein the antigen is a tumor-associated peptide.

### Claim 42 (depends on 25)

The method of claim 25, wherein the antigen is a peptide comprising an HIV-1 cluster peptide vaccine construct (CLUVAC) selected from the group consisting of:
(SEQ ID NO:1)
EQMHEDIISLWDQSLKPCVKRIQRGPGRAFVTIGK,
(SEQ ID NO:2)
KQIINMWQEVGKAMYAPPISGQIRRIQRGPGRAFVTIGK,
(SEQ ID NO:3)
RDNWRSELYKYKVVKIEPLGVAPTRIQRGPGRAFVTIGK,
(SEQ ID NO:4)
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK,
(SEQ ID NO:5)
DRVIEVVQGAYRAIRHIPRRIRQGLERRIQRGPGRAFVTIGK,
(SEQ ID NO:6)
DRVIEVVQGAYRAIRRIQRGPGRAFVTIGK,
(SEQ ID NO:7)
AQGAYRAIRHIPRRIRRIQRGPGRAFVTIGK,
(SEQ ID NO:8)
EQMHEDIISLWDQSLKPCVKRIHIGPGRAFYTTKN,
(SEQ ID NO:9)
KQIINMWQEVGKAMYAPPISGQIRRIHIGPGRAFYTTKN,
(SEQ ID NO:10)
RDNWRSELYKYKVVKIEPLGVAPTRIHIGPGRAFYTTKN,
(SEQ ID NO:11)
AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN,
(SEQ ID NO:12)
DRVIEVVQGAYRAIRHIPRRIRQGLERRIHIGPGRAFYTTKN,
(SEQ ID NO:13)
DRVIEVVQGAYRAIRRIHIGPGRAFYTTKN
and
(SEQ ID NO:14)
AQGAYRAIRHIPRRIRRIHIGPGRAFYTTKN.

### Claim 43

(canceled)

### Claim 44 (depends on 42)

The method of claim 42, wherein the HIV-1 CLUVAC is HIV-1 CLUVAC PCLUS3-18MN (SEQ ID NO:9).

### Claim 45 (depends on 42)

The method of claim 42, wherein the HIV-1 CLUVAC is HIV-1 CLUVAC PCLUS 6.1-18MN (SEQ ID NO:12).

### Claim 46

An immunogenic composition for inducing a protective mucosal CTL response in a subject and adapted for intrarectal administration comprising a purified soluble antigen formulated for intrarectal delivery to the rectum, colon, sigmoid colon, or distal colon.

### Claim 47 (depends on 46)

The immunogenic composition of claim 46, which comprises a rectal enema, foam, suppository, or topical gel.

### Claim 48 (depends on 46)

The immunogenic composition of claim 46, further comprising a base, carrier, or absorption-promoting agent adapted for intrarectal delivery.

### Claim 49 (depends on 48)

The immunogenic composition of claim 48, which includes a rectal emulsion or gel preparation.

### Claim 50 (depends on 48)

The immunogenic composition of claim 48, wherein the soluble antigen is admixed with a homogenous gel carrier.

### Claim 51 (depends on 48)

The immunogenic composition of claim 48, wherein the homogenous gel carrier is a polyoxyethylene gel.

### Claim 52 (depends on 48)

The immunogenic composition of claim 48, wherein the soluble antigen is admixed with a rectally-compatible foam.

### Claim 53 (depends on 48)

The immunogenic composition of claim 48, wherein the soluble antigen is formulated in a suppository.

### Claim 54 (depends on 53)

The immunogenic composition of claim 53, wherein the suppository is comprised of a base selected from a polyethyleneglycol, witepsol H15, witepsol W35, witepsol E85, propyleneglycol dicaprylate (Sefsol 228), Miglyol810, hydroxypropylcellulose-H (HPC), or carbopol-934P (CP).

### Claim 55 (depends on 53)

The immunogenic composition of claim 53, comprising at least two base materials.

### Claim 56 (depends on 46)

The immunogenic composition of claim 46, including a stabilizing agent to minimize intrarectal degradation of the soluble antigen.

### Claim 57 (depends on 46)

The immunogenic composition of claim 46, including an absorption-promoting agent.

### Claim 58 (depends on 57)

The immunogenic composition of claim 57, wherein the absorption-promoting agent is selected from a surfactant, mixed micelle, enamines, nitric oxide donor, sodium salicylate, glycerol ester of acetoacetic acid, clyclodextrin or beta-cyclodextrin derivative, or medium-chain fatty acid.

### Claim 59 (depends on 46)

The immunogenic composition of claim 46, further comprising an adjuvant.

### Claim 60 (depends on 59)

The immunogenic composition of claim 59, wherein the adjuvant is selected from cholera toxin (CT), mutant cholera toxin (MCT), mutant-E. coli heat labile enterotoxin, o(Original) r pertussis toxin.

### Claim 61 (depends on 59)

The immunogenic composition of claim 59, wherein the adjuvant is conjugated to a mucosal tissue or T cell binding agent.

### Claim 62 (depends on 61)

The immunogenic composition of claim 61, wherein the mucosal tissue or T cell binding agent is selected from protein A, an antibody that binds a mucosal tissue- or T-cell-specific protein, or a ligand or peptide that binds a mucosal tissue- or T-cell-specific protein.

### Claim 63 (depends on 59)

The immunogenic composition of claim 59, wherein the adjuvant comprises a recombinant cholera toxin (CT) having a B chain of CT substituted by protein A conjugated to a CT A chain to eliminate toxicity and enhance mucosal tissue binding mediated by protein A.

### Claim 64 (depends on 59)

The immunogenic composition of claim 59, wherein the adjuvant is conjugated to a protein or peptide that binds specifically to T cells.

### Claim 65 (depends on 64)

The immunogenic composition of claim 64, wherein the protein or peptide binds to CD4 or CD8.

### Claim 66 (depends on 66)

The immunogenic composition of claim 66, wherein the protein or peptide is an HIV V3 loop or T cell-binding peptide fragment thereof.

### Claim 67 (depends on 59)

The immunogenic composition of claim 59, further comprising purified IL-12.

### Claim 68 (depends on 59)

The immunogenic composition of claim 59, further comprising purified interferon-γ.

### Claim 69 (depends on 68)

The immunogenic composition of claim 68, further comprising purified IL-12.
